🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

299 results for “AVI” Clear

  1. Ozempic 0.25 mg solution for injection in pre-filled pen, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 1 mg solution for injection in pre-filled pen

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Craving for and use of chemsex-related drugs

    phase 2 small molecule active

    1 trial

  2. PALONOSETRON, Jakavi 10 mg tablets, ONDANSETRON, NETUPITANT, APREPITANT, PACRITINIB, Jakavi 5 mg tablets, SELINEXOR

    Karyopharm Therapeutics

    moderate thrombocytopenia, JAK inhibitor-naïve myelofibrosis

    phase 2 small molecule active

    1 trial

  3. Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Tislelizumab, Paclitaxel 6 mg/mL concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion

    Fondazione Telethon ETS

    Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  4. Piromelatine (Neu-P11)

    Pharma Mar S.A.

    idiopathic (isolated) Rapid Eye Movement Behavior Disorder

    phase 2 small molecule active

    1 trial

  5. Placebo to ISL, Placebo to MK-8507, Placebo to BIC/FTC/TAF, EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, islatravir, ulonivirine

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

  6. Placebo to match DNTH103, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, DNTH103, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, c

    Dianthus Therapeutics, Inc. /DE/

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  7. Povetacicept

    Vertex Pharmaceuticals (Ireland) Limited

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  8. RAVICTI 1.1 g/ml oral liquid

    Pari Pharma GmbH

    Pyruvate dehydrogenase deficiency

    phase 2 small molecule active

    1 trial

  9. Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)

    BRIGHT MINDS BIOSCIENCES INC.

    Human Papilloma Virus Infection

    phase 2 mab completed

    1 trial

  10. Ribavirin

    Vertex Pharmaceuticals (Ireland) Limited

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  11. Riboflavin

    United Therapeutics Europe Ltd

    Keratolysis

    phase 2 small molecule completed

    1 trial

  12. Ruxolitinib

    RIGEL PHARMACEUTICALS INC

    Coronavirus

    phase 2 small molecule completed

    1 trial

  13. SIKLOS PAEDIATRIC 50mg dispersible tablets

    THERAVIA

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  14. SNDX-6352

    Syndax Pharmaceuticals Inc

    Coronavirus

    phase 2 small molecule terminated

    1 trial

  15. SPR720

    Spero Therapeutics

    Mycobacterium Avium Complex

    phase 2 small molecule terminated

    1 trial

  16. Selinexor

    Karyopharm Therapeutics

    Coronavirus Infection

    phase 2 small molecule completed

    2 trials

  17. Standard Cognitive Behavioral Treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 other completed

    1 trial

  18. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  19. TAK-019

    Takeda Pharmaceuticals International AG

    Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

    phase 2 mab completed

    1 trial

  20. TAK-079

    Takeda Pharmaceuticals International AG

    Myasthenia Gravis

    phase 2 small molecule completed

    1 trial

  21. TAK-919

    Takeda Pharmaceuticals International AG

    Coronavirus Disease (COVID-19)

    phase 2 mab completed

    1 trial

  22. TENOFOVIR ALAFENAMIDE , Sodium chloride solution 0.9%, ENTECAVIR , TENOFOVIR DISOPROXIL , JNJ-73763989

    Janssen-Cilag International N.V.

    Hepatitis B and Hepatitis D Viral Co-infection

    phase 2 small molecule active

    1 trial

  23. Tenofovir/lamivudine/lopinavir-ritonavir

    China SXT Pharmaceuticals

    HIV

    phase 2 small molecule completed

    1 trial

  24. Ultravist 370 mg/ml soluzione iniettabile

    Istituto Gentili S.r.l.

    Patients with breast lesions undergoing further examination

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources